If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Furthermore, it has been observed in many retrospective longitudinal studies that corticosteroid treatment does not seem to significantly prolong survival of the native liver or transplant-free survival.
== History == Amino acid activation was first characterized by Mahlon Hoagland, who found that amino acids could be activated by certain enzymes to form an aminoacyl adenylate intermediate compound. The enzymes were discovered to be aminoacyl t-RNA synthetases, responsible for catalyzing the linkage of an amino acid to a small RNA molecule. Hoagland and his collaborator, Paul Zamecnik, later discovered that the small RNA molecule was a tRNA, and they identified it as a key facilitator of translation. Amino acid activation is a key reaction in many biochemical and metabolic processes. In particular, leucine natural killer treatment of interleukin-18 activated cells triggers the mTORC1 metabolic sensor, which indicates that mTORC1 causes amino acid-driven activation due to a high expression in amino acid transporters. The Inhibition of CD98/LAT1 amino acid transporters abroad mTORC1 activation driven by leucine, decreased the activity of the NK cell-effector.
== Causes == PAN has no association with anti-neutrophil cytoplasmic antibodies, but about 30% of people with PAN have chronic hepatitis B and deposits containing HBsAg-HBsAb complexes in affected blood vessels, indicating an immune complex-mediated cause in that subset. Infection with the hepatitis C virus and HIV are occasionally discovered in people affected by PAN. PAN has also been associated with underlying hairy cell leukemia. The cause remains unknown in the remaining cases; there may be causal and clinical distinctions between classic idiopathic PAN, the cutaneous forms of PAN, and PAN associated with chronic hepatitis. In children, cutaneous PAN is frequently associated with streptococcal infections, and positive streptococcal serology is included in the diagnostic criteria.
Sources: en.wikipedia.org
=== Foundation and early years === Medtronic was founded in 1949 in Minneapolis by Earl Bakken and his brother-in-law, Palmer Hermundslie, as a medical equipment repair shop. Bakken invented several medical technology devices that continue to be used around the world today. Through his repair business, Bakken came to know C. Walton Lillehei, a doctor of heart surgery at the University of Minnesota Medical School. The deficiencies of artificial pacemakers at the time became evident during a power outage over Halloween in 1957, which affected large sections of Minnesota and western Wisconsin. A pacemaker-dependent paediatric patient of Lillehei died because of the blackout. The next day, Lillehei spoke with Bakken about developing some form of battery-powered pacemaker. Bakken modified the design for a transistorized metronome and created the first battery-powered external pacemaker. It fit in a four-inch-square box that could be taped to a patient's chest, transmitted electrical signals to the heart through wires that passed through the patient's chest, and could be removed without surgery.
== Resources == Casss Times Archived 2006-09-28 at the Wayback Machine, Spring 2005 Casss Times Archived 2006-09-28 at the Wayback Machine, Autumn 2005 California Death Index Robert G Brownlee Marine project Archived 2014-04-15 at the Wayback Machine Article in The Scientist, June 1990 Applied Biosystems Timeline
=== Business === Suga is also a founder of PeptiDream Inc. Tokyo, a publicly traded biopharmaceutical start-up company responsible for discovering and developing non-standard peptide therapeutics in addition to addressing unmet medical needs as well as investigating peptide drug conjugates (PDC), peptides, and small molecule-based drugs. It is traded publicly on the Tokyo First Stock Exchange Market (the market capitalization is over JY 600 billions), which has many partnerships with pharmaceutical companies in worldwide. Suga is chair of the editorial board at RSC Chemical Biology and associate editor at Angewandte Chemie.
inverted repeat A nucleotide sequence followed downstream on the same strand by its own reverse complement. The initial sequence and the reverse complement may be separated by any number of nucleotides, or may be immediately adjacent to each other; in the latter case, the composite sequence is also called a palindromic sequence. Inverted repeats are self-complementary by definition, a property which involves them in many biological functions and dysfunctions. Contrast direct repeat.
Sources: en.wikipedia.org
Cyberwarfare in the United States is a part of the American military strategy of proactive cyber defence and the use of cyberwarfare as a platform for attack. The new United States military strategy makes explicit that a cyberattack is casus belli just as a traditional act of war. U.S. government security expert Richard A. Clarke, in his book Cyber War (May 2010), had defined "cyberwarfare" as "actions by a nation-state to penetrate another nation's computers or networks for the purposes of causing damage or disruption." The Economist describes cyberspace as "the fifth domain of warfare," and William J. Lynn, U.S. Deputy Secretary of Defense, states that "as a doctrinal matter, the Pentagon has formally recognized cyberspace as a new domain in warfare . . . [which] has become just as critical to military operations as land, sea, air, and space." When Russia was still a part of the Soviet Union in 1982, a portion of a Trans-Siberia pipeline within its territory exploded, allegedly due to a Trojan Horse computer malware implanted in the pirated Canadian software by the Central Intelligence Agency. The malware caused the SCADA system running the pipeline to malfunction. The "Farewell Dossier" provided information on this attack, and wrote that compromised computer chips would become a part of Soviet military equipment, flawed turbines would be placed in the gas pipeline, and defective plans would disrupt the output of chemical plants and a tractor factory.
=== Detection methods === There are many in vitro and in vivo techniques which are useful in detecting DNA-Protein Interactions. The following lists some methods currently in use: Electrophoretic mobility shift assay (EMSA) is a widespread qualitative technique to study protein–DNA interactions of known DNA binding proteins. DNA-Protein-Interaction - Enzyme-Linked ImmunoSorbant Assay (DPI-ELISA) allows the qualitative and quantitative analysis of DNA-binding preferences of known proteins in vitro. This technique allows the analysis of protein complexes that bind to DNA (DPI-Recruitment-ELISA) or is suited for automated screening of several nucleotide probes due to its standard ELISA plate formate. DNase footprinting assay can be used to identify the specific sites of binding of a protein to DNA at basepair resolution. Chromatin immunoprecipitation is used to identify the in vivo DNA target regions of a known transcription factor. This technique when combined with high throughput sequencing is known as ChIP-Seq and when combined with microarrays it is known as ChIP-chip. Yeast one-hybrid System (Y1H) is used to identify which protein binds to a particular DNA fragment. Bacterial one-hybrid system (B1H) is used to identify which protein binds to a particular DNA fragment. Structure determination using X-ray crystallography has been used to give a highly detailed atomic view of protein–DNA interactions.
===== Oceania ===== New Zealand - DMT is classified as a Class A drug under the Misuse of Drugs Act 1975. Australia - DMT is listed as a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 drug is outlined in the Poisons Act 1964 as "Substances which may be abused or misused, the manufacture, possession, sale, or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of the CEO". Between 2011 and 2012, the Australian federal government was considering changes to the Australian Criminal Code that would classify any plants containing any amount of DMT as "controlled plants". DMT itself was already controlled under current laws. The proposed changes included other similar blanket bans for other substances, such as a ban on any and all plants containing mescaline or ephedrine. The proposal was not pursued after political embarrassment on realisation that this would make the official floral emblem of Australia, Acacia pycnantha (golden wattle), illegal. The Therapeutic Goods Administration and federal authority had considered a motion to ban the same, but this was withdrawn in May 2012 (as DMT may still hold potential entheogenic value to native and/or religious people). Under the Misuse of Drugs Act 1981 6.0g (3/16oz) of DMT is considered enough to determine a court of trial and 2.0g (1/16oz) is considered intent to sell and supply. In December 2004, the U.S.
In February 2024, Senator Scott Wiener introduced the Safe and Secure Innovation for Frontier Artificial Intelligence Models Act to the California legislature. The bill drew heavily on the Biden executive order and had the goal of reducing catastrophic risks by mandating safety tests for the most powerful AI models. If passed, the bill would have established a publicly-funded cloud computing cluster in California. Governor Gavin Newsom vetoed the bill in September 2024. The Artificial Intelligence Training Data Transparency Act (AB 2013) and Transparency in Frontier Artificial Intelligence Act (TFAIA) (SB 53) went into effect on January 1, 2026. In addition, the California AI Transparency Act will go into effect in August 2026. By signing TFAIA into law in September 2025, California became the first state to enact a statute specifically addressing the development of frontier AI models. The TFAIA protects whistleblowers who have reasonable cause to believe their employers are endangering lives or causing damages worth $1 billion. It also requires companies to publish their safety test results. The political action committee Parents & Kids Safe AI Coalition, funded by OpenAI, has been involved in efforts to establish legislation related to child safety and AI in California. In September 2024, Alameda County's Board of Supervisors approved a countywide policy for agency and department usage of generative artificial intelligence (GenAI) technology.
== Specialty areas == Many medical laboratory scientists are generalists, skilled in most areas of the clinical laboratory. However, some are specialists, qualified by unique undergraduate education or additional training to perform more complex analyses than usual within a specific field. Specialties include clinical biochemistry, hematology, coagulation, microbiology, bacteriology, toxicology, virology, parasitology, mycology, immunology, immunohematology (blood bank), histopathology, histocompatibility, cytopathology, genetics, cytogenetics, electron microscopy, and IVF labs. Medical technologists specialty may use additional credentials, such as "SBB" (specialist in blood banking), "SM" (specialist in microbiology), "SC" (specialist in chemistry), or "SH" (specialist in hematology) from the American Society for Clinical Pathology (ASCP). These additional notations may be appended to the base credential, for example, "MLS (ASCP), SBB (ASCP)". Additional information can be found in the ASCP Procedures for Examination & Certification. Andrology laboratory scientist (such as those working for a sperm bank), embryology laboratory scientist, and molecular diagnostics technologist certifications are provided by the American Association of Bioanalysts; those with the certifications are classified as ALS (AAB), ELS (AAB), and MDxT (AAB), respectively.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.